Clinical Trials Logo
  1. Home
  2. Antibiotic Resistant Strain
  3. NCT03963297

Multicenter Evaluation of the Susceptibility of Enterobacteriaceae and Pseudomonas Aeruginosa to Ceftolozane/Tazobactam Combination — GMC-9  

Antibiotic Resistant Strain Clinical Trial

Official title:
Multicenter Evaluation of the Susceptibility of Enterobacteriaceae and Pseudomonas Aeruginosa to Ceftolozane/Tazobactam Combination

Clinical Trial Summary

Ceftolozane/tazobactam is a new antibiotic with broad spectrum activity. This molecule is currently one of the most active beta lactams against Pseudomonas aeruginosa and its spectrum of activity also includes enterobacteriaceae producing a broad spectrum beta-lactamase (EBLSE). Ceftolozane/tazobactam is currently marketed for the treatment of complicated intra-abdominal infections and complicated urinary tract infections. These intra-abdominal and urinary infections are mainly caused by enterobacteriaceae (Escherichia coli, Klebsiella pneumoniae) and more rarely by P. aeruginosa. Concerning enterobacteriaceae, French epidemiology reports a prevalence of BLSE of between 10 and 15% in E. coli and 10%-30% in K. pneumoniae.

Clinical Trial Description

Currently, the probabilistic treatment of these multi-resistant bacteria involves the use of carbapenems. Unfortunately, the increasing and unreasonable use of carbapenems invariably leads to the spread of even more resistant strains, BHRe (Emerging Highly Resistant Bacteria) including enterobacteriaceae producing carbapenemases. Thus, it is strongly recommended by health authorities to limit the use of carbapenems ("carbapenem savings") by promoting the use of therapeutic alternatives. Ceftolozane/tazobactam is one of those therapeutic alternatives for which an evaluation must be carried out. Currently, in addition to complicated intra-abdominal infections and complicated urinary tract infections, ceftolozane/tazobactam combination is used in clinical practice in gram-negative infections such as upper and lower respiratory infections and bacteremia. In any case, the choice of probabilistic antibiotic therapy must take into account local and regional epidemiological data. However, published data on the in vitro activity of ceftolozane/tazobactam remain limited, particularly in France (only one French epidemiological study on Gram-negative non-fermenting bacillus strains isolated in patients with cystic fibrosis). This study does not take into account in particular multi-resistant enterobacteriaceae producing BLSE for which ceftolozane/tazobactam remains effective (particularly in E. coli and K. pneumoniae). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03963297
Study type Observational
Source Groupe Hospitalier Paris Saint Joseph
Contact
Status Completed
Phase
Start date March 1, 2019
Completion date December 30, 2022
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06262009 - Dynamics of AMR Spread, Persistence and Evolution Between Humans, Animals and Their Environment
Completed NCT04212403 - Antibiotic Prophylaxis in Transurethral Prostate Resection (TURP) and Transurethral Bladder Tumour Resection (TURB) N/A
Recruiting NCT04460313 - Nasopharyngeal Carriage of S. Pneumoniae N/A
Active, not recruiting NCT03208725 - Childhood Acute Illness and Nutrition Network
Active, not recruiting NCT05027893 - Complications After Lower Third Molar Surgery N/A
Not yet recruiting NCT04795518 - The Pattern of Antibiotic Prescription for Children Among a Group of Pediatric Dentists.
Completed NCT05551988 - Predictors of Foot Amputation in Diabetic Foot Ulcers
Recruiting NCT03767283 - Carbapenem and Quinolone Resistance in Klebsiella Pneumoniae
Completed NCT03061097 - Autologous Fecal Microbiota Transplantation to Prevent Antibiotic Resistant Bacteria Colonization Phase 1
Withdrawn NCT03391674 - Fecal Microbiota Transplantation for Eradication of Carbapenem-resistant Enterobacteriaceae Colonization N/A
Recruiting NCT04107194 - Non-invasive Test-guided Tailored Therapy Versus Empiric Treatment for Helicobacter Pylori Infection. Phase 3
Completed NCT03884348 - Tailored H. Pylori Eradication Based on Clarithromycin Resistance
Completed NCT04926935 - Bloodstram Infections in ICU. Single Centre Observational Study.
Not yet recruiting NCT04269174 - The Utility of Biofire Filmarray in Evaluation of Entero Pathogens Triggers in Patients With Chronic Diarrhea
Completed NCT03167398 - Fecal Microbiota Transplantation for Eradication of CRE Phase 1/Phase 2
Completed NCT03866291 - ESBL in Patients Returning to Sweden With Traveller's Diarrhoea
Completed NCT01902589 - Resistance of Helicobacter Pylori to Antibiotics in Children N/A
Not yet recruiting NCT04593368 - Fecal Microbiome Transplantation (FMT) in Pediatric Patients Colonized With Antibiotic-resistant Pathogens Before Hematopoietic Stem Cell Transplantation (HSCT) Phase 2
Completed NCT03063437 - A Trial of Encapsulated Fecal Microbiota for Vancomycin Resistant Enterococcus Decolonization Phase 2
Active, not recruiting NCT03140410 - Linezolid-resistant Staphylococcus Epidermidis in ICU and Risk Factors Analysis N/A